GILD has seen positive price action YTD; due to combatting the COVID-19 with their drug Remdesivir. Yesterday on the news, the trial on humans which was set in China to prove the effectivity of the drug, apparently "failed". However... The price just took us to the lower part of the channel , meaning the Risk-Reward-Ratio is at a good stance. A close below...
Trade Plan for Gilead Sciences. Will look to enter at bottom of uptrend channel (75.3) , Stop Loss once uptrend broken (74). Target Price at 86. Potential Price at 96. Personally will take profit at resistances as insurance. Upside for Gilead: 1a) Possible treatment for Covid-19 (Remdesivir) 1b) Possible 2nd wave of virus 2) Possible FDA approval of Arthritis...
GILD- If you didn't hear the news, yesterday Gilead labs were accredited with a drug that has been positively treating COVID19 patients. I checked the price and it is very expensive already. I had a look at the chart today and noticed that the last time this stock crossed golden (50/200 MA) on the weekly, it skyrocketed. On top of that, it held support like a...
NASDAQ:GILD $GILD - I Mean Come On! #SuperSimpleCharts
Down to 60 / 47 up to 170 In the future. Deepest pullback to 25 zone. Don't see it happening. This will be the first bounce off the red ribbon. Usually it is always quite strong once we touch it. Good buy zones : $42 - 50 Good sell zone: $150 - 170
Gilead says that they have a coronavirus treatment in route. The chart looks great too. Worst case, we have a minor leg down to the .382 line, but long term I'm bullish. (note: I am long on calls for this into the summer.)
A good time to review the previous floor at 60.xx that we have been tracking for almost a year in $GILD. Here taking the latest misses in Q4 Earnings with a pinch of salt as the red carpet has been rolled out for Gild via China. Once again another buying opportunity given the latest progress around Phase III clinical trials: On the Remdesivir (GS-5734) side,...
Been doing research on the progress of a coronavirus cure and severity of the outbreak. My intention was never to look for companies to invest in, I was genuinely curious about the state of the world. I came across an article (replace parenthesis with period): www() bloomberg()...
GILD seems to be forming a long term bottom, the presence of two falling wedges displays the possible repeating bullish nature of this chart. Green fractal indicates a long term target price of ~100. If downsides occur a stop loss is placed. MACD can be observed to be also rising. Volume is not always a great indicator of price movement but in a more mature market...
The global slowdown is coming and it is time to get defensive. Here we are reaching the end of the road to the downside in Gilead and a perfect instrument to work the flows with. We are tracking a break of the channel to unlock the +11% move. Let's see how it plays out over the coming days. Best of luck
chart doesn't look good until we move through/ hold above ICHI cloud
Traders, i wanted to share this setup with you that i am trading. I have had this stock for a while on my watchlist, and was waiting for a correction to buy the dip. I like to buy low (cheap) in strong stocks showing upside potential. I particularly was watching the 72$ level (200DMA, 61% fibo this is a big level. The bulls seem to have made a bottom now on this...
Gilead's core product pipeline, including recent FDA approval is set to soar as key drugs and generics are continuing to outperform. The company's recent acquisition of KITE Pharma came at the perfect moment with KITE being granted a key drug approval by the FDA. Gilead's recent cost cutting efforts and R&D focus are to further push growth prospect and boost...
I don't have a position in this stock, but I am waiting patiently to enter with a medium-long term strategy. For the following reasons: 1. Appr. 50% reduction in price from all time high in USD$123 (june 2015) to USD$65 (feb 2017). 2. USD$65 is the previous support level from 2014-04-10. 3. The stock has gapped twice already 1# 2016-07-25 and 2# 2017-02-08. 4....
Current Support: 69-70 Near-Term support: 63 I like Gilead for fundo reasons (massive FCF) but the market is correctly worried about declining hep c revenues and the lack of a transformative acquisition. The trend is clearly down with regards to price, MACD, and RSI. RSI trend-line needs to reverse in order for price to appreciate in my view.
I like GILD for fundamental reasons but the market is worried about declining hep c revenues and the chart is clear. could bottom here at 69-70, but if it goes below 69 I think we revisit 63 where there is pretty strong support. RSI is in a clear downtrend, which needs to be cleared before price and momentum can reverse positively
Great company, horrible stock, looks ready to dump more. Potential support at 63-64.
Check Monthly chart. GILD is one of the fastest growing company, but had to drop their share price since Hillary want to drop Drug price. She keep repeating since last year, but it will not really damage drug price. It will actually damage CVS or insurance companies. GILD rebate a lot of money to CVS and insurance companies. Plus, Chart is very attractive and...